103 related articles for article (PubMed ID: 12152998)
1. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea.
Bruchova H; Borovanova T; Klamova H; Brdicka R
Leuk Lymphoma; 2002 Jun; 43(6):1289-95. PubMed ID: 12152998
[TBL] [Abstract][Full Text] [Related]
2. [Gene expression in white blood cells in chronic myeloid leukemia].
Bruchová H; Klamová H; Brdicka R
Cas Lek Cesk; 2000 Oct; 139(21):655-9. PubMed ID: 11192763
[TBL] [Abstract][Full Text] [Related]
3. JNK2 and p38 MAPK over-expressions do not represent key events in chronic myeloid leukemia transformation.
Merkerova M; Bruchova H; Brdicka R
Neoplasma; 2007; 54(6):503-10. PubMed ID: 17949234
[TBL] [Abstract][Full Text] [Related]
4. C-myc expression in cell lines derived from chronic myeloid leukemia.
Gómez-Casares MT; Vaqué JP; Lemes A; Molero T; Delgado MD; León J
Haematologica; 2004 Feb; 89(2):241-3. PubMed ID: 15003904
[No Abstract] [Full Text] [Related]
5. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
[TBL] [Abstract][Full Text] [Related]
6. [Interferon-alpha in the treatment of chronic myeloid leukemia].
Guilhot F
Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
[No Abstract] [Full Text] [Related]
7. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
8. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.
Merkerova M; Bruchova H; Brdicka R
Leuk Res; 2007 May; 31(5):661-72. PubMed ID: 17070905
[TBL] [Abstract][Full Text] [Related]
10. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
12. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Weide R; Dowding C; Paulsen W; Goldman J
Leukemia; 1990 Oct; 4(10):695-9. PubMed ID: 1976871
[TBL] [Abstract][Full Text] [Related]
13. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
14. Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas Cdo C; Ferreira da Cunha A; Brugnerotto AF; Gambero S; de Almeida MH; Carazzolle MF; Pagnano KB; Traina F; Costa FF; de Souza CA
Leuk Lymphoma; 2014 Aug; 55(8):1861-9. PubMed ID: 24144310
[TBL] [Abstract][Full Text] [Related]
15. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
17. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells.
Ohmine K; Ota J; Ueda M; Ueno S; Yoshida K; Yamashita Y; Kirito K; Imagawa S; Nakamura Y; Saito K; Akutsu M; Mitani K; Kano Y; Komatsu N; Ozawa K; Mano H
Oncogene; 2001 Dec; 20(57):8249-57. PubMed ID: 11781839
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
19. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
